共 50 条
Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic?
被引:12
|作者:
Ellis, Katrina L.
[1
,2
]
Watts, Gerald F.
[1
,3
]
机构:
[1] Univ Western Australia, Sch Med, 35 Stirling Highway, Crawley, WA 6009, Australia
[2] Univ Western Australia, Sch Biomed Sci, 35 Stirling Highway, Crawley, WA 6009, Australia
[3] Royal Perth Hosp, Dept Cardiol, Lipid Disorders Clin, GPO Box X2213, Perth, WA 6001, Australia
关键词:
Lipoprotein(a);
Atherosclerotic cardiovascular disease;
Pharmacotherapy;
Risk assessment;
Models of care;
HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA;
CARDIOVASCULAR-DISEASE;
DOUBLE-BLIND;
TARGETING APOLIPOPROTEIN(A);
VASCULAR RISK;
CORONARY;
APHERESIS;
DYSLIPIDEMIA;
OUTCOMES;
THERAPY;
D O I:
10.1016/j.ccl.2017.12.010
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Lipoprotein(a) is a low-density lipoprotein-like particle covalently bound to a glycoprotein called apolipoprotein(a) that is under potent genetic control. Plasma levels of lipoprotein(a) vary by up to 1000-fold among individuals, with 1 in 4 having levels that increase the risk of atherosclerotic cardiovascular disease. New evidence supports a causal role for lipoprotein(a) in atherosclerotic cardiovascular disease and aortic valve stenosis. Individuals with elevated lipoprotein(a) have a high life-time burden of atherosclerotic cardiovascular disease. This notion is important for coronary prevention. But is lipoprotein(a) ready for prime-time use in coronary prevention clinics?
引用
收藏
页码:287 / +
页数:13
相关论文